Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

    ... harboring TP53 mutation do not show a good response to lenalidomide therapy. In general, the results of this study show that ...

    Research Article last updated 02/01/2017 - 8:15am.

  2. Treatment of low-risk myelodysplastic syndromes

    ... fails ESA treatment, the available options may include lenalidomide (approved for del5q positive cases), hypomethylating agents, ...

    Research Article last updated 01/26/2017 - 10:42am.

  3. Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure

    ... agents, including 5-azacytidine, deoxyazacytidine, and lenalidomide . For patients no longer benefitting from these agents, there ...

    Research Article last updated 01/26/2017 - 10:36am.

  4. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications

    ... manifested as erythroid hypoplasia. P53 antagonism by lenalidomide or other therapeutics such as antisense oligonucleotides, ...

    Research Article last updated 01/26/2017 - 10:06am.

  5. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... June 1, 2009 Lenalidomide has proven efficacy and safety and has been shown to reduce ... System low- or intermediate-1-risk MDS who began lenalidomide therapy between April 2002 and June 2003 as part of the MDS-001 ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?

    ... agents, and the duration of response is often limited. Lenalidomide , a second-generation immunomodulatory drug (IMiD), is ... MDS patients with deletion 5q chromosomal abnormality. Lenalidomide also has meaningful clinical activity in lower-risk patients ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.

    ... immunomodulatory agents (imids) thalidomide and lenalidomide may induce transfusion independence . This guideline ... abstracts met eligibility criteria. CONCLUSIONS: Lenalidomide is recommended as first line therapy in lower risk del5q MDS. ...

    Research Article last updated 10/01/2012 - 10:04am.

  8. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

    ... April 1, 2010 Lenalidomide was approved by the US Food and Drug Administration (FDA) for ... and frequency of myelosuppression. In del(5q) patients, lenalidomide suppresses the clone by inhibiting the nuclear ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.

    ... dependence. Over recent years, the immunomodulatory drug lenalidomide has demonstrated remarkable efficacy in patients with del(5q) ... of the pathogenesis of the disease have suggested that lenalidomide targets aberrant signaling pathways caused by haplosufficiency of ...

    Research Article last updated 09/17/2013 - 2:05pm.

  10. Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

    ... October 1, 2012 Lenalidomide leads to high rates of erythroid transfusion independence ... parameters and TP53 mutations. These data also indicate that lenalidomide per se is not leukemogenic. Length of treatment can be tailored ...

    Research Article last updated 11/05/2012 - 9:37am.